# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## **SCHEDULE 13G**

Under the Securities Exchange Act of 1934 (Amendment No. n/a)\*

# GT BIOPHARMA, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

**36254L 100** (CUSIP Number)

September 1, 2017

(Date of Event Which Requires Filing of this Statement)

Check th	ne appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] F	Rule 13d-1(b)
[X] 1	Rule 13d-1(c)
[ ] F	Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1

CUSIP No.	36254L 100
1	NAMES OF REPORTING PERSONS I.R.S. INDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Mark J. Silverman
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a) [ ]
	(a) [ ] (b) [ ]
3	SEC USE ONLY
_	
4	CITIZENSHIP OR PLACE OF ORGANIZATION
7	
	United States
NUMBER OF SHARES	5 SOLE VOTING POWER
BENEFICIALLY	8,172,079
OWNED BY	6 SHARED VOTING POWER
EACH	·
REPORTING	0
PERSON WITH:	7 SOLE DISPOSITIVE POWER
	8,172,079
	8 SHARED DISPOSITIVE POWER
	0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING LERSON
	8,172,079
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE
	INSTRUCTIONS)
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11	

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

16.4%

N/A

12

T /	-
Item	
1111111	1.

(j)

[]

§ 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Name of Issuer (a) GT BIOPHARMA, INC. Address of Issuer's Principal Executive Offices (b) 1825 K Street, Suite 510 Washington, DC 20006 Item 2. (a) Name of Person Filing Mark J. Silverman Address of Principal Business Office or, if none, Residence (b) 224 22nd Street Santa Monica, CA 90402 Citizenship (c) United States Title of Class of Securities (d) Common Stock **CUSIP** Number (e) 36254L 100 Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). [] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (b) [] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (c) (d) [] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) [ ] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) [] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); [] (g) (h) [] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the (i) Investment Company Act of 1940 (15 U.S.C. 80a-3);

A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

#### Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 8,172,079

(b) Percent of class: 16.4%

(b) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 8,172,079

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 8,172,079

(iv) Shared power to dispose or to direct the disposition of: 0

#### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

N/A

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

N/A

Item 8. Identification and Classification of Members of the Group

N/A

Item 9. Notice of Dissolution of Group

N/A

#### Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 1, 2017

By: <u>/s/ Mark J. Silverman</u> Name: Mark J. Silverman

Title: Individual

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)